Purchase this article with an account.
Joseph Capriotti MD, Jesse Pelletier MD FACS, Kara Capriotti, Samuel Barone MD; Efficacy of Topical Ophthalmic Agent VBP-100 Against Multi-Drug Resistant Biofilms of Staphylococcus aureus,Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3653. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate novel topical antimicrobial VBP-100 against multi-drug resistant biofilm forming pathogens.
Biofilms of multi-drug resistant Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans were developed on solid surfaces using the Calgary Biofilm Device (CBD) plate. Minimum biofilm eradication concentration (MBEC) was then determined for each test drug and for control samples of known antibiotics, ciprofloxacin and itraconazole
VBP-100 completely eliminated all biofilms of bacterial and fungal species in the test systems. Ciprofloxacin was able to eradicate one bacterial biofilm only at concentrations greater than 0.25 ug/mL.
VBP-100 is a potent anti-bacterial and anti-fungal biofilm disrupting agent. Futher exploration in living systems is warranted.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only